Community acquired pneumonia resident survival guide: Difference between revisions

Jump to navigation Jump to search
Line 102: Line 102:
{{familytree | | | | | | | | | C02 | | | | | | C03 | | | | | | | | | C02= ❑ Infiltrates on a chest X-ray|C03=❑ No infiltrates on a chest X-ray}}
{{familytree | | | | | | | | | C02 | | | | | | C03 | | | | | | | | | C02= ❑ Infiltrates on a chest X-ray|C03=❑ No infiltrates on a chest X-ray}}
{{familytree | | | | | | | | | |!| | | | | | | |!| | | | | | | | | | }}
{{familytree | | | | | | | | | |!| | | | | | | |!| | | | | | | | | | }}
{{familytree | | | | | | | | | D01 | | | | | | D02| | | | | | | | | | D01=<div style="float: left; text-align: left; width: 20em; padding:1em; width:13em">❑ Evaluate for severity of illness using<br>❑ '''[[Pneumonia severity index]] (PSI)''' and<br> ''' CURB-65 score'''❑ Comorbid factors if any<br>❑ Start oxygenation if needed</div>|D02=<div style="float: left; text-align: left; width: 20em; padding:1em; width:13em"> ❑ [[Acute bronchitis]]<br>❑ [[Asthma]]<br>❑ [[Congestive heart failure]]<br>❑ [[Chronic obstructive pulmonary disease]]<br>❑ [[Gastroesophageal reflux disease]]<br>❑ [[Upper respiratory tract infection]]<br>❑ [[Vasculitis]]<br>❑ [[Bronchiolitis obliterans organizing pneumonia|Bronchiolitis obliterans with organizing pneumonia]]<br>❑ [[Pulmonary edema]]</div>}}
{{familytree | | | | | | | | | D01 | | | | | | D02| | | | | | | | | | D01=<div style="float: left; text-align: left; width: 20em; padding:1em; width:13em">❑ Evaluate for severity of illness using
: ❑ '''[[Pneumonia severity index]] (PSI)''' and
: ❑ ''' CURB-65 score'''
: ❑ Comorbid factors if any <br> ❑ Start oxygenation if needed</div>|D02=<div style="float: left; text-align: left; width: 20em; padding:1em; width:13em"> ❑ [[Acute bronchitis]]<br>❑ [[Asthma]]<br>❑ [[Congestive heart failure]]<br>❑ [[Chronic obstructive pulmonary disease]]<br>❑ [[Gastroesophageal reflux disease]]<br>❑ [[Upper respiratory tract infection]]<br>❑ [[Vasculitis]]<br>❑ [[Bronchiolitis obliterans organizing pneumonia|Bronchiolitis obliterans with organizing pneumonia]]<br>❑ [[Pulmonary edema]]</div>}}
{{familytree | | | | | | | | | |!| | | | | | | | | | | | | | | | | | }}
{{familytree | | | | | | | | | |!| | | | | | | | | | | | | | | | | | }}
{{familytree | | | | | | | | | E01 | | | | | | | | | | | | | | | | | | E01=❑ Start empiric therapy for<br> '''Community acquired pneumonia''' based on the <br> The PSI severity scale and <br> CURB-65 score <br> while awaiting culture results}}
{{familytree | | | | | | | | | E01 | | | | | | | | | | | | | | | | | | E01=❑ Start empiric therapy for<br> '''Community acquired pneumonia''' based on the <br> The PSI severity scale and <br> CURB-65 score <br> while awaiting culture results}}

Revision as of 19:39, 4 March 2014

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Chetan Lokhande, M.B.B.S [2]

Definition

A lower respiratory tract infection in a previously normal individual acquired through normal social contact rather than contracting it in a hospital.

Infectious Diseases Society of America/American Thoracic Society Consensus Recommendation Criteria for Severe Community Acquired Pneumonia in Adults[1]

Major Criteria:

Minor Criteria:

Causes

Life Threatening Causes

Life-threatening causes include conditions which may result in death or permanent disability within 24 hours if left untreated. Complications of community acquired pneumonia, such as pleural effusion, lung abscess, bacteremia and septicemia are life-threatening conditions and must be treated as such irrespective of the causes.

Common Causes

  • Typical Bacteria
  1. Streptococcus pneumoniae
  2. Haemophilus influenzae
  3. Escherichia coli
  4. Klebsiella pneumoniae
  5. Pseudomonas aeruginosa
  • Atypical Bacteria
  1. Mycoplasma pneumoniae
  2. Chlamydophila pneumoniae
  3. Legionella pneumophila
  • Viruses
  1. Influenza
  2. Parainfluenza
  3. Respiratory syncytial virus (RSV)
  4. Metapneumovirus
  5. Adenovirus
Common Etiologies of Community-Acquired Pneumonia
Location Etiologies of Community-Acquired Pneumonia[1][2][3]
 ▸ Outpatient Streptococcus pneumoniae
Mycoplasma pneumoniae
Haemophilus influenzae
Chlamydophila pneumoniae
Influenza A and B, adenovirus, respiratory syncytial virus, parainfluenza
Inpatient (non-ICU) Streptococcus pneumoniae
Mycoplasma pneumoniae
Chlamydophila pneumoniae
Haemophilus influenzae
Legionella
Aspiration
Influenza A and B, adenovirus, respiratory syncytial virus, parainfluenza
Yersinia enterocolitica
Inpatient (ICU) Streptococcus pneumoniae
Staphylococcus aureus
Legionella
Gram-negative bacilli
Haemophilus influenzae
Acinetobacter baumannii

Management

Shown below is an algorithm depicting the management of community acquired pneumonia according to the Infectious Diseases Society of America (IDSA) and Thoracic Society Consensus Guidelines on the Management of Community Acquired Pneumonia in Adults.

 
 
 
 
 
 
 
 
Characterize the symptoms:
❑ Fever
❑ Cough with sputum
Dyspnea
Pleuritic chest pain
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Examine the patient:
Fever and/or
Tachypnea and/or
Rales and/or
Increased TVF
❑ Calculate PaO2/FiO2 ratio
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Order Labs:
❑ Order CBC
❑ Check BUN
❑ Order a chest X-ray
❑ Perform Sputum gram stain
❑ Sputum culture
❑ Blood culture
If suspecting atypical pneumonia, obtain:
❑ Urine legionella antigen
Enyzme Immunoassay (EIA)
Immunoflorescence
❑ PCR for atypical and viral including influenza
Fibre optic bronchoscopy
❑ Biopsy for Histopathology
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
❑ Infiltrates on a chest X-ray
 
 
 
 
 
❑ No infiltrates on a chest X-ray
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
❑ Evaluate for severity of illness using
Pneumonia severity index (PSI) and
CURB-65 score
❑ Comorbid factors if any
❑ Start oxygenation if needed
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
❑ Start empiric therapy for
Community acquired pneumonia based on the
The PSI severity scale and
CURB-65 score
while awaiting culture results
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PSI score <70 = Risk Class I and II
Outpatients
with no recent antibiotic exposure
and no comorbidities
 
PSI score <70 = Risk Class I and II
Outpatients
with recent antibiotic exposure
and no comorbidities
 
 
 
 
 
PSI score > 71-90 = Risk Class III
Hospitalized patient
not in the ICU
 
PSI score 91 = Risk Class IV and V
Critically ill patients
in the ICU
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Azithromycin Oral: 500 mg on day 1 followed by 250 mg once daily on days 2-5
I.V.: 500 mg as a single dose
OR
Clarithromycin 250 mg every 12 hours for 7-14 days or 1000 mg once daily for 7 days
OR
Erythromycin 250-500 mg every 6-12 hours; maximum: 4 g daily

OR
Doxycycline Oral, I.V.: 100 mg twice daily
 
Levofloxacin 500 mg every 24 hours for 7-14 days or 750 mg every 24 hours for 5 days
OR
Moxifloxacin Oral, I.V.: 400 mg every 24 hours for 7-14 days
OR
Gemifloxacin Oral: 320 mg once daily for 5 or 7 days
OR
Amoxicillin Oral: 875 mg every 12 hours or 500 mg every 8 hours 3 times daily
OR
Amoxicillin-clavulanate 2 gm 2 times daily
OR
Other alternatives include
Ceftriaxone I.V: 1 g once daily, 2 g daily for patients at risk
OR
Cefpodoxime Oral: 200 mg every 12 hours for 14 days
OR
Cefuroxime I.M., I.V.: 750 mg every 8 hours
 
 
 
 
 
Ceftriaxone 1g IV daily
OR
Cefotaxime 1g IV q8h
PLUS
Azithromycin or Clarithromycin
'OR
❑ Respiratory fluoroquinolone (Moxifloxacin)
PLUS
Macrolide
OR
Doxycycline Oral, I.V.: 100 mg twice daily
 
Cefotaxime I.M., I.V.: 1 g every 12 hours
OR
Ceftriaxone I.V: 1 g once daily, 2 g daily for patients at risk
OR
Ampicillin-sulbactam I.V.: 1500-3000 mg every 6 hours
PLUS
Azithromycin Oral: 500 mg on day 1 followed by 250 mg once daily on days 2-5
OR
Ciprofloxacin 500-750 mg twice daily for 7-14 days
OR
Levofloxacin 500 mg every 24 hours for 7-14 days or 750 mg every 24 hours for 5 day
OR
Moxifloxacin Oral, I.V.: 400 mg every 24 hours for 7-14 days
OR
Gemifloxacin Oral: 320 mg once daily for 5 or 7 days
PLUS
Aztreonam I.V.: 2 g every 6-8 hours; maximum: 8 g daily. For penicillin allergy
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
❑ If culture results are available then treat accordingly
❑ If no response to treatment or
then look for
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pleural Effusion
 
 
 
 
 
Empyema
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Perform thoracocentesis and analyse
pH
Cell count
Gram stain
Bacterial culture
❑ Protein
Lactate dehydrogenase
 
 
 
 
 
Drain the empyema
 
 
 
 
 
 
 
 
 
 
 
 

The PSI Algorithm

The PSI Algorithm is detailed below. An online, automated PSI calculator is available on the US AHRQ website.

Step 1: Stratify to Risk Class I vs. Risk Classes II-V
Presence of:
Over 50 years of age Yes/No
Altered mental status Yes/No
Pulse ≥125/minute Yes/No
Respiratory rate >30/minute Yes/No
Systolic blood pressure ≥90 mm Hg Yes/No
Temperature <35°C or ≥40°C Yes/No
History of:
Neoplastic disease Yes/No
Congestive heart failure Yes/No
Cerebrovascular disease Yes/No
Renal disease Yes/No
Liver disease Yes/No
If any "Yes", then proceed to Step 2
If all "No" then assign to Risk Class I
Step 2: Stratify to Risk Class II vs III vs IV vs V
Demographics Points Assigned
If Male +Age (yr)
If Female +Age (yr) - 10
Nursing home resident +10
Comorbidity
Neoplastic disease +30
Liver disease +20
Congestive heart failure +10
Cerebrovascular disease +10
Renal disease +10
Physical Exam Findings
Altered mental status +20
Pulse ≥125/minute +20
Respiratory rate >30/minute +20
Systolic blood pressure ≥90 mm Hg +15
Temperature <35°C or ≥40°C +10
Lab and Radiolographic Findings
Arterial pH <7.35 +30
Blood urea nitrogen ≥30 mg/dl (9 mmol/liter) +20
Sodium <90 mmol/liter +20
Glucose ≥250 mg/dl (14 mmol/liter) +10
Hematocrit <30% +10
Partial pressure of arterial O2 <60mmHg +10
Pleural effusion +10
∑ <70 = Risk Class II
∑ 71-90 = Risk Class III
∑ 91-130 = Risk Class IV
∑ >130 = Risk Class V

CURB-65

CURB-65 is a clinical prediction rule that has been validated for predicting mortality in community-acquired pneumonia[4] and infection of any site[5]. The CURB-65 is based on the earlier CURB score[6] and is recommended by the British Thoracic Society for the assessment of severity of pneumonia.[7]


The score is an acronym for each of the risk factors measured. Each risk factor scores one point, for a maximum score of 5:

  • Confusion (defined as an AMT of 8 or less)
  • Urea greater than 7 mmol/l (Blood Urea Nitrogen > 20)
  • Respiratory rate of 30 breaths per minute or greater
  • Blood pressure less than 90 systolic or diastolic blood pressure 60 or less
  • Age 65 or older

Do's

  • Obtain a sputum gram stain, sputum culture and blood cultures before initiating antibiotic therapy.
  • Provide coverage for Streptococcus pneumoniae and atypical bacteria like (Mycoplasma, Chlamydophila, Legionella ).[8]
  • Consider acute and convalescent serologic testing to identify atypical pathogens like C.pneumoniae, Q fever and Hantavirus.
  • Perform aggressive fluid resuscitation, prompt antibiotic initiation, measure arterial blood gas in patients who have borderline hypoxemia or lactate.[9]
  • Treat co-existing illness like asthma and COPD with bronchodilators.
  • Start empirical therapy with coverage for Pseudomonas aeruginosa and MRSA if patient is hospitalized for more than 2 days.[10]
  • Give high priority to patients with elevated blood urea nitrogen (BUN), confusion and high respiratory rate.[11]:
  • First antibiotic dose should be administered within 6 hours of admission into the emergency room.[12]
  • Shock is an exception where antibiotic should be started within an hour of hypotension. A decrease in 8% of survival rate for each hour of delay is noted.[13]
  • Treat with antibiotics for atleast 5-7 days.
  • Narrow down antibiotic therapy as soon as a specific microbiological etiology is identified.
  • Chest X-ray should be performed and checked for signs of consolidation, cavitation or interstitial infiltrates.
  • Use fibre-optic bronchoscopy in immunocompromised individuals to detect less common organisms, do a tissue biopsy and identify anatomic lesions if any.

Dont's

  • Inadvertently use of antibiotic for patients without community-acquired pneumonia who require treatment before 4 hours may increase the risk of Clostridium difficile colitis.[14]Hence, use antibiotics judiciously.
  • Don't discontinue antibiotics till the patient is afebrile for 48 to 72 hours and has signs of clinical improvement.

References

  1. 1.0 1.1 Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM, Musher DM, Niederman MS, Torres A, Whitney CG (2007). "Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults". Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 44 Suppl 2: S27–72. doi:10.1086/511159. PMID 17278083. Unknown parameter |month= ignored (help)
  2. Wong, KK.; Fistek, M.; Watkins, RR. (2013). "Community-acquired pneumonia caused by Yersinia enterocolitica in an immunocompetent patient". J Med Microbiol. 62 (Pt 4): 650–1. doi:10.1099/jmm.0.053488-0. PMID 23242642. Unknown parameter |month= ignored (help)
  3. Oh, YJ.; Song, SH.; Baik, SH.; Lee, HH.; Han, IM.; Oh, DH. (2013). "A case of fulminant community-acquired Acinetobacter baumannii pneumonia in Korea". Korean J Intern Med. 28 (4): 486–90. doi:10.3904/kjim.2013.28.4.486. PMID 23864808. Unknown parameter |month= ignored (help)
  4. Lim WS, van der Eerden MM, Laing R; et al. (2003). "Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study". Thorax. 58 (5): 377–82. PMID 12728155.
  5. Howell MD, Donnino MW, Talmor D, Clardy P, Ngo L, Shapiro NI (2007). "Performance of severity of illness scoring systems in emergency department patients with infection". Academic emergency medicine : official journal of the Society for Academic Emergency Medicine. 14 (8): 709–14. doi:10.1197/j.aem.2007.02.036. PMID 17576773.
  6. Lim WS, Macfarlane JT, Boswell TC; et al. (2001). "Study of community acquired pneumonia aetiology (SCAPA) in adults admitted to hospital: implications for management guidelines". Thorax. 56 (4): 296–301. PMID 11254821.
  7. "BTS Guidelines for the Management of Community Acquired Pneumonia in Adults". Thorax. 56 Suppl 4: IV1–64. 2001. PMID 11713364.
  8. "MMS: Error".
  9. Rivers, E.; Nguyen, B.; Havstad, S.; Ressler, J.; Muzzin, A.; Knoblich, B.; Peterson, E.; Tomlanovich, M. (2001). "Early goal-directed therapy in the treatment of severe sepsis and septic shock". N Engl J Med. 345 (19): 1368–77. doi:10.1056/NEJMoa010307. PMID 11794169. Unknown parameter |month= ignored (help)
  10. "Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia". Am J Respir Crit Care Med. 171 (4): 388–416. 2005. doi:10.1164/rccm.200405-644ST. PMID 15699079. Unknown parameter |month= ignored (help)
  11. Lim, HF.; Phua, J.; Mukhopadhyay, A.; Ngerng, WJ.; Chew, MY.; Sim, TB.; Kuan, WS.; Mahadevan, M.; Lim, TK. (2013). "IDSA/ATS minor criteria aided pre-ICU resuscitation in severe community-acquired pneumonia". Eur Respir J. doi:10.1183/09031936.00081713. PMID 24176994. Unknown parameter |month= ignored (help)
  12. Wilson, KC.; Schünemann, HJ. (2011). "An appraisal of the evidence underlying performance measures for community-acquired pneumonia". Am J Respir Crit Care Med. 183 (11): 1454–62. doi:10.1164/rccm.201009-1451PP. PMID 21239689. Unknown parameter |month= ignored (help)
  13. Kumar, A.; Roberts, D.; Wood, KE.; Light, B.; Parrillo, JE.; Sharma, S.; Suppes, R.; Feinstein, D.; Zanotti, S. (2006). "Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock". Crit Care Med. 34 (6): 1589–96. doi:10.1097/01.CCM.0000217961.75225.E9. PMID 16625125. Unknown parameter |month= ignored (help)
  14. Meehan, TP.; Fine, MJ.; Krumholz, HM.; Scinto, JD.; Galusha, DH.; Mockalis, JT.; Weber, GF.; Petrillo, MK.; Houck, PM. (1997). "Quality of care, process, and outcomes in elderly patients with pneumonia". JAMA. 278 (23): 2080–4. PMID 9403422. Unknown parameter |month= ignored (help)

Template:WH Template:WS